<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01918462</url>
  </required_header>
  <id_info>
    <org_study_id>AHIL</org_study_id>
    <secondary_id>AUH</secondary_id>
    <nct_id>NCT01918462</nct_id>
  </id_info>
  <brief_title>Protective Immune Mechanisms in Alcoholic Hepatitis</brief_title>
  <acronym>AHIL</acronym>
  <official_title>Protective Immune Mechanisms in Alcoholic Hepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the production, effects and interactions of the&#xD;
      hepato-protective cytokine interleukine (IL)-22 in patients with alcoholic hepatitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will study hepatic biopsies from patients with alcoholic hepatitis. In&#xD;
      these biopsies, the investigators will assess the production of IL-22 and which cells produce&#xD;
      the cytokine. The investigators will study the expression of the IL-22 receptor and also the&#xD;
      production of the IL-22 binding protein, which can inhibit the actions of the cytokine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2013</start_date>
  <completion_date type="Actual">April 20, 2018</completion_date>
  <primary_completion_date type="Actual">April 20, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of IL-22-producing cells</measure>
    <time_frame>at day 1 ( the day of diagnosis/arrival to the department)</time_frame>
    <description>This will be detected in hepatic biopsies taken at inclusion to the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IL-22 binding protein</measure>
    <time_frame>at day 1 ( the day of diagnosis/arrival to the department)</time_frame>
    <description>This will be detected in hepatic biopsies taken at inclusion to the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-22 receptor</measure>
    <time_frame>at day 1 ( the day of diagnosis/arrival to the department)</time_frame>
    <description>This will be detected in hepatic biopsies taken at inclusion to the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Signalling molecules and markers of hepatocyte destruction</measure>
    <time_frame>at day 1, at day 7 and at day 90 after diagnosis.</time_frame>
    <description>Thse measurements will be done on blood samples drawn at inclusion, at day 7 and at day 90 after diagnosis.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">51</enrollment>
  <condition>Alcoholic Hepatitis</condition>
  <arm_group>
    <arm_group_label>Alcoholic hepatitis</arm_group_label>
    <description>Patients with alcoholic hepatic; cases.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>Persons undergoing hepatic resection; controls.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, serum, plasma, PBMC's, hepatic leukocytes&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to the Department of hepatology and gastroenterology V, Aarhus University&#xD;
        hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of alcoholic hepatitis:&#xD;
&#xD;
          -  relevant history of alcohol consumption (&gt;40g/day for a minimum of 6 months with&#xD;
             cessation of consumption no earlier than 3 months prior to admission)&#xD;
&#xD;
          -  bilirubin &gt; 80 mol/l&#xD;
&#xD;
          -  neutrophil granulocytes &gt; 10x10^9/L&#xD;
&#xD;
          -  exclusion of other liver pathology including biliary disease&#xD;
&#xD;
          -  histological verification on liver biopsy&#xD;
&#xD;
          -  Written, informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other chronic inflammatory or autoimmune diseases&#xD;
&#xD;
          -  Severe, acute bacterial infection (peritonitis, sepsis, pneumonia, urinary tract&#xD;
             infection etc.)&#xD;
&#xD;
          -  Cancer&#xD;
&#xD;
          -  Prednisolon or pentoxifylline treatment within the past 8 weeks&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sidsel St√∏y, Phd student</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of hepatology and gastroenterology, Aarhus University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Hepatology and gastroenterology V, Aarhus university hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>June 25, 2013</study_first_submitted>
  <study_first_submitted_qc>August 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2013</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alcoholic hepatitis</keyword>
  <keyword>IL-22</keyword>
  <keyword>Kupffer cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

